Abstract
BackgroundCD47-Signal-regulatory protein alpha (SIRPα) pathway is an emerging target for cancer immunotherapy. Preclinically, CD47-SIRPα blockers have been shown to enhance anti-tumor function of macrophages such as antibody-dependent cellular phagocytosis (ADCP)....
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
